CryoCor

CryoCor was a medical technology company specializing in the development of cryoablation systems for the treatment of cardiac arrhythmias. The company's core technology utilized extreme cold to create precise lesions in heart tissue, effectively blocking the abnormal electrical pathways responsible for conditions like atrial flutter and atrial fibrillation. Its flagship product, the CryoCor Cardiac Cryoablation System, was the first of its kind to receive FDA approval for treating atrial flutter. In 2008, the company was acquired by Boston Scientific, which integrated CryoCor's cryoablation expertise into its broader electrophysiology business unit.